Business brief
US Business Brief: Amazon Antitrust Suit, Eli Lilly Buyout, and Wall Street Pushback
Regulators challenge Amazon ad pricing while Eli Lilly expands drug pipelines and banks force law firms to lower AI-assisted rates.
Business
The FTC suit targets Amazon's core ad engine, claiming secret reserve prices turned standard ad auctions into a lucrative $20B fee extraction scheme.
BackgroundAmazon operates a dominant online retail marketplace alongside a high-margin advertising engine that charges merchants for top search placements. Federal regulators have increasingly targeted tech platforms that control retail marketplaces while selling access to those same platforms.
- The complaint alleges Amazon quietly altered second-price auction rules using soft floor reserves, charging winning merchant bidders full offer prices in 80% of reviewed transactions.
- Federal regulators claim the modified ad rules effectively extracted $20 billion in undisclosed fee revenue from independent merchants struggling to maintain visibility in search results.
- Amazon rejected the claims, asserting that merchant advertising costs remained flat while average conversion metrics grew 24%, showing that paid placements delivered clear seller value.
Business
Shein's lackluster debut shows public market skepticism toward fast-fashion models threatened by tightening global duty exemptions.
BackgroundShein built a massive global business by shipping cheap clothing directly from Chinese factories to overseas consumers using direct-to-consumer postal exemptions. Tightening international trade rules and labor scrutiny previously forced the company to abandon listing attempts in New York and London.
- The offering raised HK$13.6 billion but initial trading dropped before recovering slightly, reflecting public investor hesitancy around geopolitical and regulatory risks.
- Shein's $26.3 billion market capitalization represents a major valuation drop from its peak $100 billion private valuation recorded during the 2022 funding boom.
- Tightening de minimis customs exemptions in Western markets threaten Shein's low-cost shipping advantage, pressuring long-term profit margins across core retail categories.
Business
Eli Lilly is deploying cash from its GLP-1 windfall to acquire protein degradation platforms, building a hedge against future patent cliffs.
BackgroundTargeted protein degradation is an emerging therapeutic approach that uses small molecules to destroy disease-causing proteins rather than simply blocking them. Major pharmaceutical companies are buying novel biotech assets to diversify revenues before lucrative blockbuster patents expire.
- The transaction includes upfront cash plus performance milestones tied to clinical advancement, helping manage financial risk while securing early-stage platform IP.
- Merida's lead candidate MER511 enters Phase 1 trials for thyroid eye disease, giving Lilly an immediate footprint in specialized immunology markets.
- The deal marks Eli Lilly's 13th pipeline buyout this year as the drugmaker spends cash from GLP-1 weight-loss sales to build future immunology revenues.
Business
Wall Street clients are turning law firms' internal AI tools into leverage to force a collapse in traditional hourly billing rates.
BackgroundCorporate law firms raised associate and partner billing rates sharply over recent years while simultaneously adopting automated software for contract analysis and document discovery. Corporate legal departments are now pushing back against annual rate hikes by demanding shared AI efficiency savings.
- Industry legal billing data revealed average associate rates touched $798 per hour after years of compounding price hikes, fueling corporate client frustration.
- Investment banks are using internal audit software to scan law firm billing invoices and automatically flag routine tasks that AI tools can complete in seconds.
- Law firms face mounting pressure to abandon hourly billing for fixed-fee contracts on software-automated work, threatening high-margin billable hour structures.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
